Narrow Results Clear All
- Communication Improvement 1
- Education and Training 3
- Error Reporting and Analysis 4
- Human Factors Engineering 3
- Legal and Policy Approaches 1
- Quality Improvement Strategies 3
- Technologic Approaches 1
- Device-related Complications 1
- Medication Errors/Preventable Adverse Drug Events 6
- Nonsurgical Procedural Complications 1
Search results for "Anticoagulants"
- United States Federal Government
Request for comments on the proposed measures and 2020 targets for the National Action Plan for Adverse Drug Event Prevention: inpatient and outpatient measures for reduction of adverse drug events from anticoagulants, diabetes agents, and opioid analgesics.
Federal Register. Washington, DC: Office of Disease Prevention and Health Promotion, US Department of Health and Human Services. October 20, 2016;81:72594-72595.
National attention has focused on efforts to address adverse drug events. This call for comments seeks insights regarding revisions to a 2014 action plan that highlighted how to reduce adverse drug events associated with anticoagulants, diabetes agents, and opioids. These proposed updates involve measures to apply in both the inpatient and outpatient environments to track adverse drug events. The opportunity to submit written comments is now closed.
Heparin-containing medical devices and combination products: recommendations for labeling and safety testing. Draft guidance for industry and Food and Drug Administration staff.
Federal Register. Washington, DC: US Department of Health and Human Services. Baltimore, MD: Food and Drug Administration. July 9, 2015;80:39440-39441.
Journal Article > Study
Tsai TT, Maddox TM, Roe MT, et al; National Cardiovascular Data Registry. JAMA. 2009;302:2458-2464.
Patients hospitalized for cardiac problems are vulnerable to experiencing medication errors, as they are commonly prescribed high-risk medications such as anticoagulants and antiplatelet agents. This analysis of more than 22,000 hemodialysis patients undergoing percutaneous coronary interventions (PCI) (for example, angioplasty) found that 22.3% were administered either enoxaparin or eptifibatide, medications that are contraindicated in dialysis patients due to excessive bleeding risk. This risk was borne out in the study, as patients who received the contraindicated medications did in fact have more major bleeding episodes. The high prevalence of serious medication errors in this study argues for education and use of forcing functions to prevent misuse of these medications.
Audiovisual > Audiovisual Presentation
Rockville, MD: Agency for Healthcare Research and Quality, August 2010. AHRQ Publication No. 09-0086-C.
This guide provides information for consumers taking the blood thinner, warfarin.
Journal Article > Commentary
Harris Y, Hu DJ, Lee C, Mistry M, York A, Johnson TK. Jt Comm J Qual Patient Saf. 2015;41:351-360.
MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; December 6, 2012.
FDA Public Health Advisory [US Food and Drug Administration Web site]. February 28, 2008.
This announcement update alerts providers to a recall of certain heparin sodium injection vials, in response to a series of serious adverse events associated with heparin sodium injections, especially those in multiple-dose vials.
MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; January 18, 2008.
This announcement provides information on a recall of heparin vials due to negative reactions reported with certain batches of the medication.
MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; February 6, 2007.
This announcement alerts health care providers to the potential for life-threatening errors involving two heparin products and provides recommendations to minimize mistakes.
Food and Drug Administration (FDA) Patient Safety News. Show #58. December 2006.
This video story reviews a high-profile medication error and suggests actions to prevent similar incidents from occurring.
Journal Article > Study
Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system.
Budnitz DS, Pollock DA, Mendelsohn AB, Weidenbach KN, McDonald AK, Annest JL. Ann Emerg Med. 2005;45:197-206.
This project studied the epidemiologic viability of using an injury surveillance system to track outpatient adverse drug events (ADEs) treated in hospital emergency departments. The authors found that the system could play a useful role in helping to understand outpatient ADEs, identifying areas for research, and monitoring ADE prevention.